UPSC Editorial Analysis: Drug Approval Reforms in India

*General Studies-2; Topic: Government policies and interventions for development in various sectors and issues arising out of their design and implementation.*

Introduction

• The pharmaceutical sector is critical for India’s public health and economic growth.

• India is globally known as the “pharmacy of the world” for its generics and affordable vaccines, but lags in new drug discovery.

• Over the past seven years, the government has introduced several reforms to streamline the drug approval process, aiming to attract investment, boost research, and improve access to modern therapies.

Evolution of Drug Approval Reforms

• New Drugs and Clinical Trials (NDCT) Rules, 2019

• Reduced approval timelines for new therapies. Clarified procedures for clinical trials, ethics committee approvals, and compensation for trial-related injury/death. Introduced provisions for orphan drugs and “innovative therapies.”

• Reduced approval timelines for new therapies.

• Clarified procedures for clinical trials, ethics committee approvals, and compensation for trial-related injury/death.

• Introduced provisions for orphan drugs and “innovative therapies.”

• Global Reliance Pathway

• In 2023, the Drugs Controller allowed approval of medicines already cleared in US, UK, EU, Japan, Canada, and Australia without requiring local clinical trials in India. Objective: Speed up access to breakthrough drugs for Indian patients.

• In 2023, the Drugs Controller allowed approval of medicines already cleared in US, UK, EU, Japan, Canada, and Australia without requiring local clinical trials in India.

• Objective: Speed up access to breakthrough drugs for Indian patients.

• Proposed Amendments (2024–25)

• Health Ministry has invited comments on proposals to further expand the list of products exempted from local trials. Aim: Fast-track therapies for TB, cancer, Alzheimer’s, and autoimmune disorders.

• Health Ministry has invited comments on proposals to further expand the list of products exempted from local trials.

• Aim: Fast-track therapies for TB, cancer, Alzheimer’s, and autoimmune disorders.

Significance of Nimble Regulation

• Faster Access to Medicines Enables patients to receive life-saving therapies quickly. Critical for diseases with high burden in India (TB, cancer, rare diseases).

• Enables patients to receive life-saving therapies quickly.

• Critical for diseases with high burden in India (TB, cancer, rare diseases).

• Boost to Research and Innovation Reduces regulatory delays, encouraging companies to bring novel molecules. Supports India’s aspiration to be a global hub for biotech and pharma R&D.

• Reduces regulatory delays, encouraging companies to bring novel molecules.

• Supports India’s aspiration to be a global hub for biotech and pharma R&D.

• Economic Benefits Attracts foreign investment in clinical research. Strengthens India’s position in global value chains of pharmaceuticals.

• Attracts foreign investment in clinical research.

• Strengthens India’s position in global value chains of pharmaceuticals.

Challenges in Drug Discovery and Regulation

• Regulatory Bottlenecks

• Despite reforms, India’s system is still documentation-heavy. Clinical trial approvals often face delays in ethics clearances and inspections.

• Despite reforms, India’s system is still documentation-heavy.

• Clinical trial approvals often face delays in ethics clearances and inspections.

• Weak R&D Ecosystem

• India excels in generics but lacks strong innovation in new molecules. CSIR’s collaborations with academia and industry over 15 years show promise but remain limited.

• India excels in generics but lacks strong innovation in new molecules.

• CSIR’s collaborations with academia and industry over 15 years show promise but remain limited.

• Institutional Gaps

• Deloitte–Assocham (2023) highlighted key challenges: Inadequate drug regulation capacity. Shortage of advanced testing facilities. Weak monitoring of quality compliance in manufacturing.

• Inadequate drug regulation capacity.

• Shortage of advanced testing facilities.

• Weak monitoring of quality compliance in manufacturing.

Safety Concerns in Abbreviated Trials

• Genetic and Immune Therapies Drugs that alter genetic material or immune cells carry long-term unknown risks. Need careful assessment in India’s genetically diverse population.

• Drugs that alter genetic material or immune cells carry long-term unknown risks.

• Need careful assessment in India’s genetically diverse population.

• Risk of Skipping Local Trials Local trials help assess dose-response, efficacy, and side effects specific to Indian populations. Example: Variations in drug metabolism among populations due to genetic differences.

• Local trials help assess dose-response, efficacy, and side effects specific to Indian populations.

• Example: Variations in drug metabolism among populations due to genetic differences.

• Monitoring Mechanisms Experts suggest strengthening post-marketing surveillance (pharmacovigilance). US FDA and European Medicines Agency have strong systems — India must replicate such models.

• Experts suggest strengthening post-marketing surveillance (pharmacovigilance).

• US FDA and European Medicines Agency have strong systems — India must replicate such models.

Global Comparisons

• US & EU: Emphasize rigorous Phase I–IV trials and robust post-approval monitoring.

• Japan & Australia: Allow conditional approvals for innovative drugs but mandate follow-up studies.

• India: Moving towards global reliance but needs balance between speed and safety.

Way Forward

• Strengthen Regulatory Institutions Invest in capacity building of the Central Drugs Standard Control Organisation (CDSCO). Establish advanced testing laboratories across India.

• Invest in capacity building of the Central Drugs Standard Control Organisation (CDSCO).

• Establish advanced testing laboratories across India.

• Balanced Policy Approach Fast-track approvals for rare diseases and urgent therapies. Mandatory local bridging studies for high-risk drugs.

• Fast-track approvals for rare diseases and urgent therapies.

• Mandatory local bridging studies for high-risk drugs.

• Enhance Pharmacovigilance Strengthen post-marketing surveillance like the US and EU. Digital platforms for reporting adverse drug reactions.

• Strengthen post-marketing surveillance like the US and EU.

• Digital platforms for reporting adverse drug reactions.

• Promote R&D Ecosystem Public–private partnerships to reduce cost of drug discovery. Leverage PLI schemes for pharma innovation.

• Public–private partnerships to reduce cost of drug discovery.

• Leverage PLI schemes for pharma innovation.

• International Collaboration Build synergies between Indian labs and global pharma companies. Participation in WHO-led collaborative trials (e.g., Solidarity Trial for COVID-19).

• Build synergies between Indian labs and global pharma companies.

• Participation in WHO-led collaborative trials (e.g., Solidarity Trial for COVID-19).

Conclusion

• India is at a crossroads in its pharmaceutical regulation journey. On one hand, nimble rules can unlock innovation and global competitiveness. On the other, rushing approvals without adequate safeguards may compromise patient safety.

• The government must strike a careful balance — encouraging cutting-edge medicine while ensuring robust clinical evidence, regulatory integrity, and patient welfare.

“India is the pharmacy of the world but not the laboratory of the world.” Critically analyze this statement in the context of India’s drug discovery and innovation ecosystem. (250 Words)